Inhibikase Therapeutics, Inc.
NASDAQ:IKTBiotechnology
+$0.06 today
- Market cap
- $193.57M
- Beta
- 0.97
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.52
Volume 0.43M
Average 1.03M
IKT Total Liabilities
Everything the company owes to creditors and other parties.
Inhibikase Therapeutics, Inc.NASDAQ: IKT
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 33.2% from a year ago
Total liabilities stood at $5.71M at the end of Q1 FY2026, down 33.2% from a year earlier and down 31.2% from the prior quarter. Over 3 fiscal years it compounded at +28.6% a year.
Context
- Total liabilities amounted to 3.3% of total assets at the end of Q1 FY2026, down 5.8 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -33.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 8.3M USD
- Year-over-year change
- +122.3%
- 4-year CAGR
- +19.6%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.3M | +122.3% |
| FY2024 | 2024-12-31 | 3.73M | +5.8% |
| FY2023 | 2023-12-31 | 3.53M | -9.5% |
| FY2022 | 2022-12-31 | 3.9M | -3.8% |
| FY2021 | 2021-12-31 | 4.05M | — |
Total Liabilities vs competitors
How IKT compares with its peers on the latest reported figures
- IKT's Mar 2026 total liabilities of $5.71M is the 5th highest of the 8 companies compared; the peer median is $6.23M.
- Its year-over-year change of -33.2% is the 6th highest of 7, against a peer median of +2.1%.
- Total liabilities amounts to 3.3% of total assets for IKT, versus a peer median of 62.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $414.44M | -20.7% | +2.5% | 222.3% | |
| Mar 2026 | $398.86M | +265.4% | +177.3% | 330.4% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $12.53M | — | — | 67.2% |
| Mar 2026 | $6.23M | -44.5% | +11.5% | 17.2% | |
| Mar 2026 | $5.71M | -33.2% | +28.6% | 3.3% | |
| Mar 2026 | $5.24M | +263.9% | +97.2% | 49.8% | |
EXOZeXoZymes, Inc. | Mar 2026 | $2.49M | -5.8% | +25.2% | 62.0% |
| Mar 2026 | $2.44M | +10.0% | +28.2% | 18.6% | |
| Peer median (excluding IKT) | $6.23M | +2.1% | +26.7% | 62.0% | |
Competitors are the stored peer set for IKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 40.75M | 7.19M | 9.17M | 56.49M | 139.22M |
| Short-term Investments | 0 | 15.86M | 4.09M | 41.05M | 39.54M |
| Net Receivables | 110.14K | 39.88K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 107K | 1.12M | 739.18K | 106.31K | 343.37K |
| Total Current Assets | 42.47M | 24.37M | 14.21M | 98.45M | 180.11M |
| Property, Plant & Equipment (Net) | 0 | 565.18K | 295.6K | 148.54K | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 1.1M |
| Total Non-current Assets | 0 | 565.18K | 295.6K | 148.54K | 1.1M |
| Total Assets | 42.47M | 24.94M | 14.51M | 98.6M | 181.2M |
| Account Payables | 1.09M | 1.15M | 646.77K | 943.02K | 1.16M |
| Short-term Debt | 248.91K | 0 | 381.78K | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 635.45K | 0 | 6.32M |
| Total Current Liabilities | 4.05M | 3.7M | 3.44M | 3.73M | 8.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 205.45K | 90.12K | 0 | 0 |
| Total Liabilities | 4.05M | 3.9M | 3.53M | 3.73M | 8.3M |
| Common Stock | 25.16K | 4.22K | 6.19K | 69.36K | 131.69K |
| Retained Earnings | (29.82M) | (47.87M) | (66.9M) | (94.42M) | (142.68M) |
| Accumulated OCI | 0 | 104.72K | 877 | (37.25K) | 21.8K |
| Other Stockholders Equity | 0 | 0 | 0 | 777 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 38.42M | 21.04M | 10.98M | 94.87M | 172.9M |
| Total Debt | 248.91K | 351.29K | 622K | 110.52K | 0 |
| Net Debt | (40.5M) | (6.84M) | (8.54M) | (56.38M) | (139.22M) |
Inhibikase Therapeutics, Inc.
NASDAQ:IKT
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.